Explore ›
Finding
Finding
improvement
MRD-negative status by flow cytometry at Day 29 and Day 84 of chemotherapy was strongly prognostic of long-term survival in AYA patients with ALL treated on both ABFM and hyper-CVAD, with Day 29 MRD-negative patients achieving 5-year OS of 75% versus 40% for MRD-positive patients.
| Effect size | 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29 |
| Follow-up | 5 years |
| Comparator | MRD-positive status at Day 29 or Day 84 of chemotherapy |
| Effect summary | improvement; 5-year OS 75% MRD-negative vs 40% MRD-positive at Day 29 |
Connected entities
Interventions
Conditions
Outcomes
Populations
Source
PMC5558853
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen